QL Biopharm

QL Biopharm was founded in September 2018, under Beijing QL Biopharmaceutical Co., Ltd., focusing on the development of recombinant protein drugs for chronic metabolic diseases and age-related diseases using E. coli.Currently, QL Biopharm has eight recombinant protein biosimilars and innovative biologics under research, concentrating on treating chronic metabolic diseases (such as diabetes, obesity, non-alcoholic fatty liver disease, cardiovascular diseases, etc.), age-related diseases (such as osteoporosis), and some rare diseases. Among them, RP005 is a dual-activator compound targeting diabetes and non-alcoholic fatty liver disease, aimed at diabetic patients with comorbid non-alcoholic steatohepatitis.